This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Spectrum Pharma Said to Make Bid for Allos

Stocks in this article: AMAG ALTH SPPI

WESTMINSTER, Co. ( TheStreet) -- Allos Therapeutics (ALTH) is thinking about leaving Amag Pharmaceuticals (AMAG) at the merger altar to run away with another suitor.

The suitor is offering more money for Allos than Amag but remains officially unidentified. The new bidder, however, is believed to be Spectrum Pharmaceuticals (SPPI), sources tell TheStreet.

In a regulatory filing Wednesday, Allos said it will begin negotiations with "Company A" based on a proposal to acquire Allos for $2.20 a share in cash and stock.

Company A's rival offer is composed of $1.50 in cash and 70 cents in stock, valuing Allos at $233 million. Company A's proposal, therefore, surpasses the current all-stock merger agreement with Amag that values Allos at $193 million, based on Amag's Tuesday's closing stock price.

Allos, in its regulatory filing, was careful not to endorse Company A's offer or declare it superior to the Amag merger deal. However, the mere fact that Allos' board voted to begin negotiations with Company A sends a message that the Amag deal may be unraveling.

A shareholder vote on the Amag-Allos merger is scheduled for Oct. 21.

Spectrum Pharmaceuticals is a logical answer for the identity of the mystery suitor trying to woo away Allos from Amag. Spectrum currently sells two cancer drugs -- Fusilev for colon cancer and the non-Hodgkin's lymphoma drug Zevalin.

Adding Allos' lymphoma drug Folotyn would give Spectrum a third cancer drug to sell with its existing sales force, increasing revenue and profits without having to necessarily add much to the company's marketing budget. Folotyn has been a commercial disappointment which is why Allos is seeking a buyer, so Spectrum's ability to sell the drug any more effectively is far from guaranteed.

In a previous regulatory filing, Allos identified Company A as a publicly traded pharmaceutical company with a market capitalization of less than $500 million.

Spectrum's current market cap is around $400 million. The company is cash-flow positive and ended the second quarter with $165 million in cash on its books.

At the time, Company A offered $2 a share in cash and stock for Allos, which Allos' board considered and rejected. The sweetened $2.20 a share offer, which importantly includes more cash, seems to have swayed Allos to change its mind and at least enter into talks.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs